89bio Unveils Key Insights from ENLIVEN Phase 2b Trial
89bio, Inc. (NASDAQ: ETNB), a biopharmaceutical company committed to innovative therapies for liver and cardiometabolic diseases, is preparing to share significant analyses from its Phase 2b ENLIVEN trial. This study evaluated the effects of pegozafermin, particularly among patients grappling with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. These findings will be presented in four poster presentations at the eminent American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024, set to take place soon.
Details of ENLIVEN Presentations
Key details regarding the presentations are as follows:
Biomarker Response in High-Risk MASH Patients
The first presentation, titled "Biomarker response in metabolic dysfunction-associated steatohepatitis (MASH) patients with high-risk baseline FAST scores: Observations from the ENLIVEN Phase 2b trial with pegozafermin," will be led by Dr. Naim Alkhouri. This research explores the biomarker responses among high-risk patients and will be shared on November 15, from 8:00 AM to 5:00 PM PST.
Post-Hoc Analysis on Cirrhosis Progression
On the same day, an additional poster by Dr. Jörn M. Schattenberg will delve into how pegozafermin influences cirrhosis progression, showcasing a post-hoc analysis from the ENLIVEN study. This presentation emphasizes the prospects of halting the severity of this serious condition.
Integration of Machine Learning for Treatment Insights
Saturday, November 16, will feature a presentation by Oliver Mansbach, which will focus on the innovative integration of machine learning techniques for assessing treatment responses. This can provide valuable insights in understanding patient treatments effectively.
Diagnostic Analysis of Fibrosis Scoring
Another focal point is Naim Alkhouri's work on "Diagnostic potential of FAST and AGILE3+ scores for F2/F3 fibrosis," contributing to the clinical understanding of diagnosing fibrosis based on trial results.
Understanding MASH and Its Implications
Metabolic dysfunction-associated steatohepatitis (MASH), which is often referred to as nonalcoholic steatohepatitis (NASH), is a serious, progressive condition that indicates advanced liver damage. It affects fat accumulation in the liver and fosters inflammation, leading to fibrosis, which can ultimately necessitate liver transplants in severe cases. Alarmingly, it is projected to affect millions in the U.S. by the end of the decade.
Insights from ENLIVEN Trial Design
The ENLIVEN trial is pivotal, utilizing a multicenter, randomized design to assess the safety and efficacy of pegozafermin in individuals diagnosed with biopsy-confirmed MASH. Over 192 participants were involved, each receiving weekly or bi-weekly doses of the treatment or a placebo. The trial highlighted significant primary outcomes, showcasing high statistical significance.
Exploring the Potential of Pegozafermin
Pegozafermin is an engineered analog of fibroblast growth factor 21 (FGF21), designed to alleviate complications associated with metabolic dysfunction and steatohepatitis. The treatment aims to reduce liver fibrosis while enhancing metabolic activity, including lipid and glucose metabolism, which are critical to patients' overall health. With the promising results from the trial, pegozafermin obtained both Breakthrough Therapy designation from the FDA and Recognition as Priority Medicines from the EMA, underscoring its potential among competitors.
About 89bio
Based in San Francisco, 89bio is on a mission to bring transformative therapies to those affected by liver and cardiometabolic diseases, particularly addressing conditions like MASH and hypertriglyceridemia. Through robust clinical trials, including the prospective ENLIVEN study, the organization is committed to making strides in treatment efficacy and patient care.
Frequently Asked Questions
What is the ENLIVEN trial?
The ENLIVEN trial is a Phase 2b study designed to evaluate the efficacy and safety of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH).
When and where will the AASLD 2024 meeting take place?
The AASLD The Liver Meeting® 2024 will occur from November 15 to 19 in San Diego.
Who is leading the poster presentations at AASLD?
Dr. Naim Alkhouri and Dr. Jörn M. Schattenberg are among the prominent figures leading these presentations.
What potential does pegozafermin have?
Pegozafermin has shown promising results in improving liver health and could prevent cirrhosis in patients with MASH.
How can one learn more about 89bio?
For more information, you can visit 89bio's official website.
